Biotherapy

Biotherapy, also called biological therapy or biological response modifier therapy in older oncology literature, is a broad cancer-treatment category built around living systems and biologically derived substances. The term is historically important because many therapies once grouped together as biotherapy are now described more precisely as immunotherapy, monoclonal antibody therapy, cell therapy, cancer vaccines, cytokine therapy, oncolytic virus therapy, antibody-drug conjugates, bispecific antibodies, or targeted biologic therapy.

In cancer care, biotherapy generally refers to treatments that help the immune system recognize cancer, change immune signaling, bind to cancer-cell targets, block growth pathways, deliver toxic payloads to malignant cells, or replace and expand immune cells outside the body before returning them to the patient. This makes the category different from one-size-fits-all cytotoxic chemotherapy. A biotherapy record should always identify the exact drug, product, cell therapy, antibody, vaccine, cytokine, virus, or biologic mechanism being discussed.

How it connects to cancer

Cancer can evade normal immune defenses by hiding antigens, suppressing T cells, recruiting inhibitory cells, or sending checkpoint signals such as PD-1, PD-L1, or CTLA-4 that tell immune cells to stand down. Modern immunotherapy tries to reverse those escape mechanisms. Checkpoint inhibitors release immune brakes, CAR T-cell therapy and tumor-infiltrating lymphocyte therapy expand or engineer immune cells, cancer vaccines attempt to educate the immune system, and cytokines such as interleukins or interferons can stimulate immune activity in selected situations.

Other biologic approaches are less directly immune-based but still fit the older biotherapy umbrella. Monoclonal antibodies can bind to cancer targets, recruit immune destruction, block receptors, or carry chemotherapy or radioactive material. Bispecific antibodies can bring T cells into contact with tumor cells. Oncolytic viruses can infect and disrupt tumor cells while stimulating immune recognition. Targeted biologics can block growth signals, angiogenesis, or survival pathways that a tumor depends on.

Clinical use

Biotherapy may be used before surgery, after surgery, with chemotherapy or radiation, as maintenance treatment, as treatment for recurrent or metastatic disease, or as part of a clinical trial. The exact role depends on the cancer type, stage, biomarkers, prior treatments, performance status, and available approvals. Examples include checkpoint inhibitors for melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, mismatch repair-deficient cancers, and other biomarker-defined tumors; CAR T-cell products for selected leukemias, lymphomas, and myeloma; monoclonal antibodies in breast, colorectal, blood, and other cancers; and BCG as a long-used immune therapy for non-muscle-invasive bladder cancer.

Biotherapy is therefore best treated as a family of related treatment strategies rather than a single protocol. Some entries are mainstream standard-of-care oncology treatments supported by randomized trials and regulatory approvals. Others are investigational, clinic-specific, repurposed, complementary, or still controversial. For database purposes, the most useful record names the specific agent and connects it to the disease setting where evidence exists.

Safety and limitations

Safety varies widely by treatment. Immune checkpoint inhibitors can cause immune-related inflammation in the skin, thyroid, lungs, liver, colon, endocrine glands, heart, kidneys, or nervous system. Cell therapies can cause cytokine release syndrome, neurologic toxicity, low blood counts, infection risk, and prolonged immune suppression. Monoclonal antibodies can cause infusion reactions, allergic reactions, target-related toxicity, or interactions with chemotherapy. Cytokines can cause fever, fatigue, low blood pressure, capillary leak, and organ stress in selected regimens.

Effectiveness is also variable. Some patients have durable responses, including long remissions in certain cancers, while others have no benefit or eventually develop resistance. Biomarker testing, tumor sequencing, immune profiling, prior treatment history, and careful monitoring are central to selecting and managing these therapies. Biotherapy should be discussed with an oncology team familiar with the specific cancer type and the exact biologic treatment being considered.

Patient use and reported experiences

Patients often report biotherapy differently than chemotherapy because side effects may be delayed, inflammatory, or immune-related rather than classic nausea and hair loss. Some report durable tumor control, improved quality of life, or fewer day-to-day symptoms. Others report fatigue, fever, rashes, diarrhea, endocrine changes, pneumonitis, neurologic symptoms, infusion reactions, or financial and logistical burdens. Public discussion also includes experimental and alternative uses of immune stimulation, so reports should be tied back to the exact product, disease, and clinical context.